60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Companyâs products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
äŒæ¥ã³ãŒãSXTP
äŒç€Ÿå60 Degrees Pharmaceuticals Inc
äžå Žæ¥Jul 12, 2023
æé«çµå¶è²¬ä»»è
ãCEOãDow (Geoffrey S)
åŸæ¥å¡æ°3
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jul 12
æ¬ç€Ÿæåšå°1025 Connecticut Avenue Nw
éœåžWASHINGTON
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·20036
é»è©±çªå·12023275422
ãŠã§ããµã€ãhttps://60degreespharma.com/
äŒæ¥ã³ãŒãSXTP
äžå Žæ¥Jul 12, 2023
æé«çµå¶è²¬ä»»è
ãCEOãDow (Geoffrey S)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã